Table 1.
Demographic and treatment characteristics of the participants and non-participants
| Participants (N=385) | Non-participants (N=113) | p-value | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Sex | |||||
| Male | 162 | (42.08) | 56 | (49.56) | 0.15 |
| Female | 223 | (57.92) | 57 | (50.44) | |
| Race | |||||
| White | 347 | (90.13) | 104 | (92.04) | 0.79 |
| Non-white | 38 | (9.87) | 9 | (7.96) | |
| Diagnosis | |||||
| Leukemia | 205 | (53.25) | 65 | (57.52) | 0.08 |
| Lymphoma | 96 | (24.94) | 16 | (14.16) | |
| Bone or soft tissue sarcoma | 43 | (11.17) | 20 | (17.70) | |
| Neuroblastoma | 15 | (3.90) | 7 | (6.19) | |
| Wilms tumor | 14 | (3.64) | 2 | (1.77) | |
| Other | 12 | (3.12) | 3 | (2.65) | |
| Age at diagnosis | |||||
| 0-4 years | 129 | (33.51) | 43 | (38.05) | 0.19 |
| 5-9 years | 102 | (26.49) | 36 | (31.86) | |
| 10-14 years | 80 | (20.78) | 14 | (12.39) | |
| 15-20 years | 74 | (19.22) | 20 | (17.70) | |
| Age at questionnaire | |||||
| 18-24 years | 19 | (4.94) | 8 | (7.08) | 0.06 |
| 25-29 years | 49 | (12.73) | 22 | (19.47) | |
| 30-34 years | 58 | (15.06) | 21 | (18.58) | |
| 35-39 years | 95 | (24.68) | 26 | (23.01) | |
| 40-44 years | 92 | (23.90) | 27 | (23.89) | |
| 45+ years | 72 | (18.70) | 9 | (7.96) | |
| Time since diagnosis | |||||
| 10-19 years | 41 | (10.65) | 9 | (7.96) | 0.02 |
| 20-29 years | 158 | (41.04) | 63 | (55.75) | |
| 30+ years | 186 | (48.31) | 41 | (36.28) | |
| Cranial radiation | |||||
| None | 221 | (57.40) | 64 | (56.64) | 0.7 |
| 1-23 Gy | 58 | (15.06) | 13 | (11.50) | |
| 24 Gy | 87 | (22.60) | 29 | (25.66) | |
| 25+ Gy | 19 | (4.94) | 7 | (6.19) | |
| Chest radiation | |||||
| None | 286 | (74.29) | 89 | (78.76) | 0.77 |
| 1-19 Gy | 18 | (4.68) | 5 | (4.42) | |
| 20-29 Gy | 29 | (7.53) | 6 | (5.31) | |
| 30+ Gy | 52 | (13.51) | 13 | (11.50) | |
| High dose Intravenous methotrexate | |||||
| None | 301 | (78.18) | 81 | (71.68) | 0.21 |
| 1-9,999 mg/m2 | 33 | (8.57) | 13 | (11.50) | |
| 10,000-29,999 mg/m2 | 34 | (8.83) | 9 | (7.96) | |
| 30,000 + mg/m2 | 17 | (4.42) | 10 | (8.85) | |
| Intrathecal methotrexate | |||||
| None | 191 | (49.61) | 54 | (47.79) | 0.76 |
| 1-99 mg/m2 | 84 | (21.82) | 24 | (21.24) | |
| 100-249 mg/m2 | 87 | (22.60) | 25 | (22.12) | |
| 250+ mg/m2 | 23 | (5.97) | 10 | (8.85) | |
| Anthracyclines | |||||
| None | 148 | (38.44) | 40 | (35.40) | 0.59 |
| 1-99 mg/m2 | 82 | (21.30) | 25 | (22.12) | |
| 100-349 mg/m2 | 98 | (25.45) | 35 | (30.97) | |
| 350+ mg/m2 | 57 | (14.81) | 13 | (11.50) | |
| Employment status | |||||
| Unemployed | 90 | (23.38) | |||
| Professional | 162 | (42.08) | |||
| Service Worker | 73 | (18.96) | |||
| Production/construction/outdoor work | 60 | (15.58) | |||
| Personal income | |||||
| None | 90 | (23.38) | |||
| < $20,000/year | 56 | (14.55) | |||
| $20-39.000/year | 95 | (24.68) | |||
| $40-59.000/year | 52 | (13.51) | |||
| $60,000+/year | 58 | (15.06) | |||
| Educational attainment | |||||
| College graduate | 163 | (42.34) | |||
| Not a college graduate | 222 | (57.66) | |||
Gy=Gray, mg/m2=milligrams per meter squared